2,5-diketo-L-gluconic acid reductases and methods of use

Details 2,5-diketo-L-gluconic acid reductases and methods of use 2,5-diketo-L-gluconic acid reductases and methods of use

2000-10-04

2003-06-10

Achutamurthy, Ponnathapu (Department: 1652)

Chemistry: molecular biology and microbiology

Enzyme , proenzyme; compositions thereof; process for...

Oxidoreductase

C435S320100, C435S252300, C435S243000, C435S440000, C536S023200

Reexamination Certificate

active

06576452

ABSTRACT:

FIELD OF THE INVENTION
The present invention relates to naturally occurring and recombinant variants of 2,5-diketo-D-gluconic acid reductase. More specifically, the invention relates to the isolation, identification and use of 2,5-diketo-D-gluconic acid reductases.
BACKGROUND OF THE INVENTION
Conversion of glucose to vitamin C (ascorbic acid) is a complicated process because it involves the selective epimerization, oxidation, and lactone formation. The natural biosynthetic pathways are long and incorporate many energy-consuming reactions (Davey, et al.,
Plant Physiol.
121(2):535-43 (1999); Nishikimi, M and K. Yagi,
Subcell Biochem.
25:17-39 (1996); Wheeler, et al.,
Nature
393(6683):365-9 (1998). The current commercial process for ascorbic acid production (the Reichstein process) couples a single, initial biological step—the microbial reduction of glucose to sorbitol—with subsequent, multi-step chemical conversion of blocked derivatives of sorbitol to ascorbic acid (Crawford, T. C.,
American Chemical Society, Washington, D.C.
(1982); Reichstein, T. and A. Grussner,
Helv. Chim. Acta
16:311 (1934)). An alternative commercial process has been proposed that consists of biological conversion of glucose to 2-keto-L-gulonic acid which is lactonized chemically to ascorbic acid (Anderson, et al.,
Science
230:144-149 (1985); Grindley, et al.,
Appl. Environ. Microbiol.
54:1770-1775 (1988); Sonoyama, et al., U.S. Pat. No. 3,922,194 (1975)). The biological metabolism involved is simpler than that of natural biosynthetic routes and requires less metabolic energy (less ATP and NADPH). In this process, glucose is first converted to 2,5-diketo-D-gluconic acid by endogenous oxidases of a suitable bacterial strain using molecular oxygen as the ultimate electron acceptor. 2,5-diketo-D-gluconic acid is then reduced enzymatically to 2-keto-L-gulonic acid by a heterologous 2,5-diketo-D-gluconic acid reductase (DKGR) expressed in the production strain. The NADPH required for the reaction is generated by the metabolism of the host strain. Finally, chemical lactonization of 2-keto-L-gulonic acid generates ascorbic acid.
To date, only two 2,5-diketo-D-gluconic acid reductases have been extensively characterized, both isolated from a species of Corynebacterium (Miller, et al.,
J. Biol. Chem.
262(19):9016-20; Powers, D. B. and S. Anderson, U.S. Pat. No. 5,795,761 (1998); Sonoyama, T. and K. Kobayashi,
J. Ferment. Technol.
65:311-317 (1987)). These enzymes are able to reduce 2,5-diketo-D-gluconic acid, but alternative or altered reductases could improve ascorbic acid production by the process described above or variations of it. Both of the Corynebacterium enzymes are relatively inefficient catalysts, exhibiting K
m
values for 2,5-diketo-D-gluconic acid greater than 1 mM and catalytic efficiencies (k
cat
/K
m
) less than 20 mM
−1
sec
−1
.
2,5-diketo-D-gluconic acid reductases are members of the aldo-keto reductase superfamily (Jez, et al.,
Biochem J.
326(Pt3):625-36 (1997); Seery, et al.,
J Mol Evol.
46(2):139-46 (1998)). Like almost all other aldo-keto reductases, the known 2,5-diketo-D-gluconic acid reductases are exclusively specific for NADPH (Jez, et al.,
Biochem J.
326(Pt3):625-36 (1997); Seery,
J Mol Evol.
46(2):139-46 (1998)). Recently, additional aldo-keto reductases that can convert 2,5-diketo-D-gluconic acid to 2-keto-L-gulonic acid have been isolated from
E. coli
based on a search of the genome sequence (Yum, et al.,
Bacteriol.
180(22):5984-8 (1998); Yum, et al.,
Appl Environ Microbiol.
65(8):3341-6 (1999)). However, these enzymes also catalyze the reaction relatively inefficiently. The known 2,5-diketo-D-gluconic acid reductases also lack stability; both Corynebacterium enzymes are thermally labile (Powers, D. B. and S. Anderson, U.S. Pat. No. 5,795,761 (1998); Sonoyama, T. and K. Kobayashi,
J. Ferment. Technol.
65:311-317 (1987)).
It would therefore be desirable to solve the problem of inefficient reductases by providing 2,5-diketo-D-gluconic acid reductases which are more efficient than known reductases. In particular, it would be desirable to provide novel enzymes which display greater catalytic efficiency than previously known 2,5-diketo-D-gluconic acid reductases, and which have NADH-dependant activity. It would further be desirable for the reductase to be more stable thermally than known 2,5-diketo-D-gluconic acid reductases. It would further be desirable to provide variants of said reductases, methods of making, screening and using novel reductases.
SUMMARY OF THE INVENTION
The present invention provides nucleic acids, proteins, microorganisms and methods of making and using the same, which each involve reductases of the superfamily of aldo-keto reductases.
In one embodiment, an isolated nucleic acid molecule comprising a nucleic acid sequence which encodes a peptide having an amino acid sequence which has at least about 60% sequence identity to an amino acid sequence as set forth in
FIG. 2A
(SEQ ID NO:8) or
2
B (SEQ ID NO:10) is provided. In another embodiment, said nucleic acid molecule consists essentially of said nucleic acid sequence. In another embodiment, said amino acid sequence has at least about 70%, 80%, or as much as 90% sequence identity to said amino acid sequence of
FIG. 2A
(SEQ ID NO:8) or
2
B (SEQ ID NO:10). Fragments of said nucleic acids are also provided herein.
In another embodiment, the isolated nucleic acid molecule provided herein comprises a nucleotide sequence as set forth in
FIG. 2A
(SEQ ID NO:7) or
2
B (SEQ ID NO:9), or a fragment thereof.
In another aspect of the invention, an isolated nucleic acid molecule is provided herein which comprises a sequence having at least about 50%, 55%, or 60% sequence identity to a sequence selected from the group of sequences set forth in
FIG. 1
(SEQ ID NO:1-6). In another embodiment, said nucleic acid molecule consists essentially of a sequence having at least about 50%, 55%, or 60% identity to a sequence of
FIG. 1
(SEQ ID NO:1-6). In another embodiment, said sequence has at least about 70%, 80%, or as much as 90% sequence identity to said sequence of
FIG. 1
(SEQ ID NO:1-6). In another embodiment, a nucleic acid is provided herein which has a sequence selected from the sequences as set forth in
FIG. 1
(SEQ ID NO:1-6). Fragments of said nucleic acids are also provided herein.
In yet a further embodiment, a nucleic acid provided herein encodes a protein having activity of a reductase from the aldo-keto reductase superfamily. In preferred embodiments, said protein comprises 2,5-diketo-D-gluconic acid reductase activity.
Also provided herein is an expression vector comprising any one or more of the nucleotide sequences provided herein. Also provided herein is a microorganism comprising one or more of said vectors. Preferably, said microorganism is of Pantoea.
Further provided herein is polypeptide comprising an amino acid sequence having at least about 60% identity to an amino acid sequence as set forth in
FIG. 2A
(SEQ ID NO:8) or
2
B (SEQ ID NO:10). Preferably, said polypeptide comprises 2,5-diketo-D-gluconic acid reductase activity. In another embodiment, said polypeptide has at least 70% sequence identity with said amino acid sequence of
FIG. 2A
(SEQ ID NO:8) or
2
B (SEQ ID NO:10). In a further embodiment a polypeptide is provided herein that has an amino acid sequence as set forth in
FIG. 2A
(SEQ ID NO:8) or
2
B (SEQ ID NO:10). Fragments of the polypeptides provided herein are also provided.
In yet a further aspect of the invention, provided herein are variants of the nucleic acids and polypeptides provided herein. Generally, the variants are mutated internally and/or at the amino and/or carboxyl terminus so as to have an altered activity from the wildtype. In one embodiment, said polypeptide has a Q at a position corresponding to position 232 and/or position 238 of the amino acid sequence shown in
FIG. 2A
(SEQ ID NO:7).
In preferred embodiments, reductases are provided herein which have one or more improved or altered qualities or characteristics ov

Affiliated with

Also associated with

Rating

2,5-diketo-L-gluconic acid reductases and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 2,5-diketo-L-gluconic acid reductases and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2,5-diketo-L-gluconic acid reductases and methods of use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3134468